Skip to Main Content

Paper Details

Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitors.
Nat Cancer
91
2020
Alpelisib, ESR1, HR, MBC, PI3K, PIK3CA, PIK3CA mutant, PTEN, PTEN mutations, alpelisib, aromatase, hormone, hormone receptor, maculopapular rash, metastatic breast cancers, patients, plasma circulating tumor DNA, tumor
Author NameAffiliation
David N BrownMemorial Sloan Kettering Cancer Center
Ronglai ShenMemorial Sloan Kettering Cancer Center
Pier SelenicaMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerWeill Cornell Medical College
Clifford A HudisMemorial Sloan Kettering Cancer Center
Clifford A HudisWeill Cornell Medical College
Clifford A HudisAmerican Society of Clinical Oncology
Larry NortonMemorial Sloan Kettering Cancer Center
Larry NortonWeill Cornell Medical College
Larry NortonMemorial Sloan Kettering Cancer Center
Larry NortonWeill Cornell Medical College
Rebecca NagyInc.
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
  • 1 - 17

Datasets

Release 1.2